Phoenix, AZ—Arizona Center for Cancer Care (AZCCC) a leading cancer treatment center, is proud to be the first positron emission tomography (PET) center in Arizona to offer PYLARIFY® (piflufolastat F 18) Injection. PYLARIFY® is a radioactive diagnostic agent indicated for positron emission tomography of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. PYLARIFY® offered by Lantheus Pharmaceutical received FDA approval in May 2021 and is now available.
One in eight men will be diagnosed with prostate cancer and is the second most common cancer among men next to skin cancer. The American Cancer Society estimates that in 2021 there will roughly 250,000 prostate cancer diagnoses and 35,000 deaths.
“We are excited to be able to offer personalized treatment options for prostate cancer patients based on the true stage of each individual patient’s disease. This innovative technology allows us to customize treatment plans for newly diagnosed and recurrent prostate cancer by improving our ability to determine where the cancer is when compared to older methods.” Dr. Gregory Maggass, MD, Radiation Oncologist, Arizona Center for Cancer Care.
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
Find more information here: https://www.pylarify.com/biochemical-pca
For over a decade, Arizona Center for Cancer Care has provided multi-specialty treatment to more than 30,000 cancer patients across the Valley and prides itself on the importance of serving the entire family. Arizona Center for Cancer Care’s mission is to provide the highest quality cancer treatment in Arizona. At AZCCC, patients can depend on the absolute best doctors and staff for cancer care. They are a cancer center without walls with services stretching across the Valley and beyond.
Contact: Jenny Martin firstname.lastname@example.org 414-378-8703